Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Neoadjuvant IBI110 and Sintilimab In Combination With Chemotherapy In Resectable Locally Advanced Head And Neck Squamous Cell Carcinoma (HNSCC)- a Phase Ib Clinical Trial

Next Previous
Trial Profile

Neoadjuvant IBI110 and Sintilimab In Combination With Chemotherapy In Resectable Locally Advanced Head And Neck Squamous Cell Carcinoma (HNSCC)- a Phase Ib Clinical Trial

Status: Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 04 Mar 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Cisplatin (Primary) ; Docetaxel (Primary) ; IBI 110 (Primary) ; Paclitaxel (Primary) ; Sintilimab (Primary)
  • Indications Carcinoma; Head and neck cancer; Squamous cell cancer
  • Focus Therapeutic Use

Most Recent Events

  • 25 Feb 2025 Planned number of patients changed from 20 to 27.
  • 25 Feb 2025 Status changed from active, no longer recruiting to recruiting.
  • 19 Jul 2024 New trial record

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top